Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
|Articles|June 6, 2016
Shire to Create Up to 200 Jobs at Baxalta Facility
June 06, 2016
Advertisement
Shire plans to retain and expand Baxalta’s drug research outpost in Kendall Square, following its $32 billion purchase of Baxalta Inc., the
The takeover sees Shire employ more than 3,000 workers in Massachusetts, making it the state’s second largest biopharma employer, after Sanofi Genzyme, the Globe adds.
Shire CEO Flemming Ornskov said Shire plans to expand Baxalta’s 400-person research center at Kendall Square by 100 to 200 jobs and keep an office at the research center "as a window on the entrepreneurial activity in the area".
Read the Boston Globe report
Advertisement
Related to this article
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
MFN Is an Offer Pharma Can’t Refuse
4
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
5